Stephens Investment Management Group LLC Sells 7,070 Shares of Repligen Co. (RGEN)

Stephens Investment Management Group LLC lessened its holdings in Repligen Co. (NASDAQ:RGEN) by 0.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 912,362 shares of the biotechnology company’s stock after selling 7,070 shares during the period. Stephens Investment Management Group LLC owned 2.09% of Repligen worth $33,100,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. PNC Financial Services Group Inc. boosted its stake in Repligen by 162.8% in the second quarter. PNC Financial Services Group Inc. now owns 5,635 shares of the biotechnology company’s stock valued at $234,000 after buying an additional 3,491 shares in the last quarter. Palisade Capital Management LLC NJ boosted its stake in Repligen by 4.5% in the third quarter. Palisade Capital Management LLC NJ now owns 658,979 shares of the biotechnology company’s stock valued at $25,252,000 after buying an additional 28,646 shares in the last quarter. Perceptive Advisors LLC bought a new position in Repligen in the third quarter valued at about $3,349,000. Boston Advisors LLC raised its position in Repligen by 17.9% in the third quarter. Boston Advisors LLC now owns 139,483 shares of the biotechnology company’s stock valued at $5,345,000 after purchasing an additional 21,185 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Repligen by 9.7% in the second quarter. Vanguard Group Inc. now owns 1,984,393 shares of the biotechnology company’s stock valued at $82,233,000 after purchasing an additional 175,191 shares during the last quarter. 83.48% of the stock is currently owned by hedge funds and other institutional investors.

In related news, CEO Anthony Hunt sold 8,970 shares of the business’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $35.95, for a total transaction of $322,471.50. Following the sale, the chief executive officer now directly owns 83,613 shares in the company, valued at approximately $3,005,887.35. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Howard Benjamin sold 12,729 shares of the business’s stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $35.34, for a total value of $449,842.86. Following the transaction, the vice president now owns 36,554 shares of the company’s stock, valued at $1,291,818.36. The disclosure for this sale can be found here. Company insiders own 1.50% of the company’s stock.

Shares of Repligen Co. (NASDAQ RGEN) traded up $0.37 during trading on Wednesday, reaching $32.32. The company’s stock had a trading volume of 155,600 shares, compared to its average volume of 239,461. The firm has a market capitalization of $1,391.91, a PE ratio of 54.78, a PEG ratio of 1.79 and a beta of 0.91. Repligen Co. has a 12-month low of $29.56 and a 12-month high of $46.81.

Several equities analysts have commented on RGEN shares. BidaskClub downgraded Repligen from a “hold” rating to a “sell” rating in a research report on Wednesday, February 7th. Citigroup assumed coverage on Repligen in a research report on Friday, December 8th. They set a “buy” rating and a $45.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on Repligen in a research note on Tuesday, December 5th. They set an “overweight” rating and a $42.00 target price for the company. Zacks Investment Research cut Repligen from a “buy” rating to a “hold” rating in a research note on Wednesday, January 24th. Finally, Jefferies Group reaffirmed a “hold” rating and set a $40.00 target price on shares of Repligen in a research note on Thursday, October 19th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $44.38.

COPYRIGHT VIOLATION WARNING: This report was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/14/stephens-investment-management-group-llc-sells-7070-shares-of-repligen-co-rgen.html.

Repligen Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply